Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Nurix Therapeutics (NRIX) EBIT (2019 - 2025)

Nurix Therapeutics (NRIX) has disclosed EBIT for 7 consecutive years, with -$83.1 million as the latest value for Q4 2025.

  • On a quarterly basis, EBIT fell 28.52% to -$83.1 million in Q4 2025 year-over-year; TTM through Nov 2025 was -$285.7 million, a 34.1% decrease, with the full-year FY2025 number at -$285.7 million, down 34.1% from a year prior.
  • EBIT was -$83.1 million for Q4 2025 at Nurix Therapeutics, up from -$91.4 million in the prior quarter.
  • In the past five years, EBIT ranged from a high of -$24.5 million in Q1 2021 to a low of -$91.4 million in Q3 2025.
  • A 5-year average of -$47.8 million and a median of -$45.5 million in 2022 define the central range for EBIT.
  • Peak YoY movement for EBIT: crashed 99.65% in 2021, then soared 41.45% in 2023.
  • Nurix Therapeutics' EBIT stood at -$38.0 million in 2021, then fell by 28.29% to -$48.7 million in 2022, then rose by 6.89% to -$45.3 million in 2023, then crashed by 42.62% to -$64.7 million in 2024, then decreased by 28.52% to -$83.1 million in 2025.
  • Per Business Quant, the three most recent readings for NRIX's EBIT are -$83.1 million (Q4 2025), -$91.4 million (Q3 2025), and -$48.3 million (Q2 2025).